Why Investors Loved Intercept Pharmaceuticals' Q3 Update
Intercept Pharmaceuticals (NASDAQ: ICPT) really needed some good news. Its shares have plunged by more than 70% year to date, with most of the decline coming after the Food and Drug Administration gave a thumbs-down to obeticholic acid (OCA) as a treatment for non-alcoholic steatohepatitis (NASH).
The drugmaker announced its third-quarter results before the market opened on Monday, and it delivered at least some good news for investors. Here are the highlights.
Image source: Getty Images.
Source Fool.com
